GUANGJI PHARMA.(SZ:000952) Dong Jian Yan Bao·2025-06-12 15:24Group 1: General Information - The research is about Guangji Pharmaceutical Co., Ltd. in the chemical pharmaceutical industry [2][16] - The research date is June 12, 2025, and the company's reception staff includes the general manager, board secretary, and financial director [16] Group 2: Research Institutions - The research institutions are the investors participating in the "Improving Quality and Efficiency, Strengthening Confidence, Advancing Steadily for Development" - 2025 Online Collective Investor Reception Day for Listed Companies in Hubei Province through the Panorama Roadshow Network Platform [17] Group 3: Core Views - The company will focus on the "Second Entrepreneurship" high - quality development strategy, aiming to complete various business indicators by enhancing product competitiveness, integrating resources, revitalizing assets, strengthening compliance management, and deepening management reform [24] Group 4: Q&A Summary - The company did not pay dividends in 2024 due to non - profitability. In the future, it will consider dividend matters based on various factors [22][23] - The company has submitted a registration application for human milk oligosaccharide products and will actively promote industrialization [23] - US trade policies have a certain impact on the company's orders. The current tariff on vitamin B2 products is 20%, and the additional tariffs are on the exemption list. The company will closely monitor policy trends [23] - Regarding the completion ratio of the "double - half" task of the company's main indicators as of the end of May 2025, investors are advised to refer to the company's regular reports [23] - In 2025, the company's vitamin product orders in the European market are basically flat [24]